Resveratrol prevents interleukin-1β-induced dysfunction of pancreatic β-cells

Fang Chen, Xiao‐Hua Zhou, Lin Yan, Changwen Jing, Tao Yang, Yong Ji, Yujie Sun, Xiao HanJournal of Biomedical Research 2010 · DOI

TL;DR

This study investigates how resveratrol, a natural compound found in plants like grapes, protects pancreatic beta cells from damage caused by Interleukin-1 beta (IL-1β). The findings reveal that resveratrol can prevent IL-1β-induced nitric oxide production and insulin secretion impairment, offering a potential therapeutic avenue for diabetes.

What Problem Does This Paper Address?

Type 1 and type 2 diabetes mellitus are characterized by pancreatic beta cell dysfunction. A key player in this dysfunction is Interleukin-1 beta (IL-1β), a pro-inflammatory cytokine. IL-1β triggers the production of nitric oxide (NO) via inducible nitric oxide synthase (iNOS), which in turn impairs insulin secretion and leads to beta cell damage. While resveratrol has shown promise in various health contexts, its specific protective mechanisms against IL-1β-induced beta cell dysfunction were not fully elucidated. This paper aims to clarify how resveratrol intervenes in this process, focusing on its impact on NO production, iNOS expression, and key signaling pathways like PPAR-γ and NF-κB.

Methods

The researchers employed a multi-pronged approach to investigate resveratrol's effects:

  • NO Assay (Griess Method): This standard colorimetric assay was used to quantify nitric oxide (NO) production in RINm5F cells (a rat insulinoma cell line) and isolated rat pancreatic islets treated with IL-1β and/or resveratrol.
  • Real-time Reverse Transcription PCR (RT-PCR): This technique was used to measure the mRNA levels of iNOS, allowing the researchers to assess how resveratrol affects iNOS gene expression.
  • Western Blotting: This method was used to determine the protein levels of iNOS, as well as the translocation of NF-κB (specifically the p65 subunit) between the cytoplasm and nucleus. This helps understand how resveratrol influences protein expression and cellular signaling.
  • Transient Transfection and Luciferase Reporter Assays: This approach was used to measure the transcriptional activity of PPAR-γ. Cells were transfected with a PPAR-γ luciferase reporter construct, and luciferase activity was measured to assess PPAR-γ's regulatory function.
  • Electrophoretic Mobility Shift Assay (EMSA): This technique was used to assess the DNA-binding activity of NF-κB. Nuclear extracts were analyzed to determine if resveratrol could inhibit NF-κB's ability to bind to its target DNA sequences.
  • Glucose-Stimulated Insulin Secretion Assay: Isolated rat islets were used to measure insulin secretion in response to varying glucose concentrations after treatment with IL-1β and resveratrol. This directly assesses the functional impact on insulin release.
  • MTT Assays: This assay was used to evaluate the viability of RINm5F cells to determine if resveratrol or IL-1β had any cytotoxic effects.

Datasets

Not discussed in the paper. The study utilized cell lines (RINm5F) and primary cells (isolated rat pancreatic islets) as experimental models.

Key Insights and Ideas

  • Resveratrol as a Shield: The study strongly suggests resveratrol acts as a protective agent for pancreatic beta cells against IL-1β-induced damage.
  • Targeting NO Production: A primary mechanism identified is resveratrol's ability to significantly suppress IL-1β-induced nitric oxide (NO) production. This is a crucial finding as NO is a major mediator of beta cell dysfunction.
  • Downstream of iNOS: Resveratrol's inhibition of NO is directly linked to its ability to reduce both iNOS mRNA and protein expression, indicating it acts at the transcriptional and translational levels.
  • PPAR-γ Activation: The research highlights that resveratrol enhances the activity of PPAR-γ, a nuclear receptor known for its protective roles. This activation appears to be a key step in resveratrol's protective cascade.
  • NF-κB Inhibition: A critical finding is that resveratrol's enhancement of PPAR-γ activity leads to the inhibition of NF-κB activation. NF-κB is a pro-inflammatory transcription factor that drives iNOS expression, so its suppression is vital.
  • Functional Restoration: Beyond molecular mechanisms, resveratrol was shown to restore impaired glucose-stimulated insulin secretion in isolated islets, demonstrating a direct functional benefit.
  • No Cytotoxicity: Importantly, resveratrol demonstrated these protective effects without negatively impacting beta cell viability, suggesting a favorable safety profile.

Key Results

  • Resveratrol significantly inhibited IL-1β-induced NO production in a dose-dependent manner.
  • Resveratrol attenuated IL-1β-induced increases in iNOS mRNA and protein expression in both RINm5F cells and rat islets.
  • IL-1β significantly decreased PPAR-γ transcriptional activity, while resveratrol reversed this effect.
  • Resveratrol inhibited IL-1β-induced translocation of NF-κB (p65) from the cytoplasm to the nucleus and reduced its transcriptional activity.
  • Resveratrol prevented IL-1β-induced inhibition of glucose-stimulated insulin secretion in isolated rat islets.
  • Neither IL-1β nor resveratrol alone significantly affected the viability of RINm5F cells.

Limitations and Future Work

  • Cell Line vs. Primary Cells: While both a cell line (RINm5F) and primary rat islets were used, further studies in more complex in vivo models would be beneficial to confirm these findings.
  • Specific PPAR-γ Pathway: While the study shows resveratrol enhances PPAR-γ activity and this leads to NF-κB inhibition, a more detailed dissection of the specific downstream targets and signaling intermediates within the PPAR-γ pathway could be explored.
  • Clinical Translation: The findings are promising for type 2 diabetes, but clinical trials would be necessary to determine the efficacy and safety of resveratrol supplementation in human patients.
  • Synergistic Effects: Investigating potential synergistic effects of resveratrol with other anti-diabetic agents could be a valuable future direction.

Summary updated

BibTeX
@article{chen2010resveratrol,
  author = {Fang Chen and Xiao‐Hua Zhou and Lin Yan and Changwen Jing and Tao Yang and Yong Ji and Yujie Sun and Xiao Han},
  title = {{Resveratrol prevents interleukin-1β-induced dysfunction of pancreatic β-cells}},
  journal = {Journal of Biomedical Research},
  year = {2010},
  doi = {10.1016/s1674-8301(10)60051-6},
}
Figure